Dilek Çağlayan

7PUBLICATIONS
64CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 27, 2026
Integrated Inflammatory and Nutritional Biomarkers in Metastatic Renal Cell Carcinoma Treated with Second- or Later-Line Nivolumab: A Retrospective Cohort Study.

|Jul 28, 2026
Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.

|Feb 19, 2026
Safe use of ribociclib in a patient with HR+/HER2- metastatic breast cancer receiving chronic hemodialysis.

Dilek Çağlayan, Melek Çağlayan

|Jan 28, 2026
The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study.

Engin Hendem, Mehmet Zahid Koçak, Ayşegül Merç Çetinkaya

|Dec 19, 2025
The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study.

Bilgeşah Kılıçtaş, Murat Araz, Ahmet Oruç

|Nov 10, 2025
Do Inflammatory and Nutritional Markers Predict Prognosis in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab.

Esra Zeynelgil, Dilek Çağlayan, Selahattin Çelik

Pageof 2

Frequent Collaborators

3 joint publications

Murat Araz

3 joint publications

Mehmet Artaç

2 joint publications

Mehmet Zahid Koçak

2 joint publications

Melek Çağlayan